Exhibit 1
JOINT FILING AGREEMENT
The undersigned hereby agree that this Schedule 13D (as may be amended from time to time, the “Schedule 13D”) with respect to the common stock of Conduit Pharmaceuticals Inc. beneficially owned by the undersigned is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
| Date: September 29, 2023 | ||
Corvus Capital Ltd. | ||
| By: | /s/ Andrew Regan | |
| Name: | Andrew Regan | |
| Title: | Chief Executive Officer | |
| Date: September 29, 2023 | ||
Algo Holdings, Inc. | ||
| By: | /s/ Alexander Lambert | |
| Name: | Alexander Lambert | |
| Title: | Director | |
| Date: September 29, 2023 | ||
Andrew Regan | ||
| By: | /s/ Andrew Regan | |
